May 2006 Edition 

Medical Marijuana – The FDA Loses More Credibility
© Cancer Monthly, 2006

Every month, Cancer Monthly summarizes the latest clinical results of cancer therapies presented by oncologists, researchers, and other cancer professionals working in over 340 hospitals and research institutions around the world. With this information, patients can compare treatments, have more meaningful discussions with their doctors, and ultimately, make more informed treatment decisions.

This month we report on the FDA’s efforts to eliminate the use of medical marijuana.  This attempt ignores government sponsored research that demonstrates that marijuana has therapeutic value in pain relief, control of nausea and vomiting, and appetite stimulation and also kills cancer cells invitro.

Disclaimer - Please Read: Of course, none of this information in CancerWire is a substitute for professional medical advice, examination, diagnosis or treatment and you should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. No information contained in Cancer Monthly or CancerWire including the information below, should be used to diagnose, treat, cure or prevent any disease without the supervision of a medical doctor.

Medical Marijuana – The FDA Looses More Credibility
© Cancer Monthly 2006

The FDA is getting the reputation of letting drug company representatives make decisions for the country (see Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings), approving dangerous drugs (see Frontline interview with Sidney Wolfe, MD), and not performing follow-up on approved drugs (see “FDA says firms still lagging on follow-up drug studies).  Now, add to this list the fact that the FDA throws science out the window and makes decisions that have no basis in reality.  This bureaucracy recently stated that “smoked marijuana has no currently accepted or proven medical use in the United States...”  This statement was made apparently without any research and demonstrates that the needs of cancer patients play little if any role in the decisions of this disgraceful organization. 

In 1999, the government’s own prestigious Institute of Medicine looked at this issue and published a report titled: “Marijuana and Medicine: Assessing the Science Base.”  Their conclusions included, “The accumulated data indicate a potential therapeutic value for cannabinoid drugs, particularly for symptoms such as pain relief, control of nausea and vomiting, and appetite stimulation. The therapeutic effects of cannabinoids are best established for THC, which is generally one of the two most abundant of the cannabinoids in marijuana…The combination of cannabinoid drug effects (anxiety reduction, appetite stimulation, nausea reduction, and pain relief) suggests that cannabinoids would be moderately well suited for particular conditions, such as chemotherapy-induced nausea and vomiting and AIDS wasting.”

In fact, there are literally hundreds of articles that appear in the peer reviewed medical and scientific literature that discuss marijuana’s effects in pain relief, control of nausea and vomiting, and appetite stimulation.  Just last month an article in the Journal of Ethnopharmacology concluded that, “Cannabinoids present an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases (cancer and AIDS), analgesics, and in the treatment of multiple sclerosis, spinal cord injuries, Tourette's syndrome, epilepsy and glaucoma.”

Beyond ameliorating the side-effects of chemotherapy, research also suggests that marijuana may play a role in killing cancer cells.  Recent journal articles have discussed how the chemicals in marijuana (i.e. delta9-THC) suppress or inhibit the growth of a variety of cancer cells invitro including breast cancers cells, brain cancer (glioblastoma cells), and leukemia cells.  See for example:

Breast CancerCannabinoids and cancer

Brain – Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

Leukemia – Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells.

In fact, the knowledge that cannabinoids suppress Lewis lung carcinoma cell growth has been known for 30 years.

The FDA’s illogical position not only ignores peer reviewed medical research, but also disregards nearly 5,000 years of history.  Cannabis has been used for medicinal purposes for over 4,800 years. Surviving texts from China, Greece and Persia confirm that its psychoactive properties were recognized, and the ancient doctors used it for a variety of illnesses and ailments. These included a whole host of gastrointestinal disorders, insomnia, headaches and as a pain reliever, frequently used in childbirth. In fact, cannabis was listed in the United States Pharmacopeia from 1850 until 1942.  (For more background see Medical cannabis.) 

The legal situation is now as confused as the political one.  There is a split between the US federal and state governments over medical marijuana policy. On June 6, 2005, the Supreme Court, in Gonzales v. Raich, ruled in a 6-3 decision that Congress has the right to outlaw medicinal marijuana, thus subjecting all patients to federal prosecution even in states where the treatment is legalized.  Not all Feds agree. In 1988, Francis L. Young, an administrative law judge with the Drug Enforcement Agency, declared that, “Marijuana, in its natural form, is one of the safest therapeutically active substances known to man.  By any measure of rational analysis marijuana can be safely used within a supervised routine of medical care.” See In The Matter of Marijuana Rescheduling Petition Of Docket No. 86-22, September 6, 1988, pp. 58-59.  Currently, there are eleven states with medical marijuana laws on the books: Alaska, California, Colorado, Hawaii, Maine, Montana, Nevada, Oregon, Rhode Island, Vermont, and Washington.

Obviously smoking marijuana is not risk-free especially to respiratory organs and tissue.  However, compared to the risks of a typical chemotherapy agent such as cytoxan which includes: urinary bladder, myeloproliferative, or lymphoproliferative malignancies, potential sterility, urinary system hemorrhagic cystitis, hematuria, cardiac toxicity, anaphylactic reactions, significant suppression of immune responses, and sometimes fatal, infections; the risks of marijuana pale in comparison. And for cancer patients with advanced cancers who want to improve the quality of their life, a risk versus benefit analysis weighs heavily on the benefit side.  Unfortunately, the FDA’s unsupportable position will only slow down the progress in researching the applications and efficacy of this plant in cancer.

Cancer Monthly provides cancer patients with the results of hundreds of therapies for advanced and metastatic cancers so that patients can compare treatments, have more meaningful discussions with their doctors, and ultimately, make more informed treatment decisions. With Cancer Monthly, patients and clinicians can: 
Access the results of hundreds of different cancer therapies;
Sort by survival rate, side effects, and hospital;
Learn which treatments offered the longest survival;
Discover the side effects experienced by other cancer patients;
Avoid highly toxic and failed therapies;
Discover the FDA-approval status of various drugs;
Contact doctors who use specific treatments;
Print out the medical summary of each treatment to share with your own physician.

Chemotherapy Assays

DiaTech Oncology - DiaTech’s New Technology can report to a physician specifically which chemotherapy agent would benefit a cancer patient by testing that patient’s live cancer cells. Drug sensitivity profiles differ significantly among cancer patients even when diagnosed with the same cancer. Knowing the drug sensitivity profile of a specific cancer patient allows the treating oncologists to prescribe chemotherapy that will be the most effective against the tumor cells of that patient. Call (877) 434-2832 for more information.

Financial Services

Assignable Life Assets was founded in 1989 as an advocacy group to represent and assist terminally ill people in exchanging their life insurance policies for immediate much-needed cash. In the last 16 years, Assignable Life Assets has helped thousands of individuals. If you are looking for a way to help pay for medical care or alternative treatments or just an opportunity to live your life with dignity, Assignable Life Assets may be able to assist you. Phone: (800) 422-1314

Immune Boosting Products

Get Healthy - This company provides a variety of immune boosting nutritional supplements designed to enhance the immune system.

Herbal Fields Supplements - Herbal Fields offers an expanding line of natural, herbal supplements for your personal health maintenance needs, including curcumin. Their site has about 160 various pages of information.

Polyerga® Plus - Polyerga® Plus is a unique nutritional supplement for supporting the immune system. Although this German-developed spleen peptide technology has been used in Europe and Asia for decades, it is only now becoming available in America. Laboratory and clinically tested to improve key immune system parameters, these peptides help to regulate and stabilize the immune system.

Legal Services

Brain Cancer Misdiagnosis Information Center - Brain Cancer Misdiagnosis Information Center provides information on the frequency of brain cancer misdiagnosis, how you can find out if you have been misdiagnosed, and what you can do about it.  The Center is run by the law firm of Webb, Scarmozzino & Gunter.

Cancer Law Center - The Cancer Law Center is comprised of attorneys with experience in helping cancer patients whose disease was made worse because of a delay in diagnosis or whose cancer treatment led to severe injuries. While many people hesitate to contact a lawyer, patients should consider their legal rights if their medical condition was made worse by medical neglect.

Goldberg, Persky & White, P.C. - This law firm (and its predecessor law firms) has been a pioneer in asbestos litigation in the United States. The attorneys of Goldberg, Persky & White, P.C. (GPW) have been involved in asbestos and mesothelioma lawsuits since 1978. Their experienced mesothelioma lawyers participated in the gathering of evidence, such as the testimony of corporate executives and doctors, and the accumulation of corporate documents, that helped create the basis for successfully suing the asbestos industry. GPW has represented thousands of mesothelioma, lung cancer, and asbestosis victims. Because of their involvement in asbestos litigation from the beginning, GPW has a clear understanding of what is required to succeed. In addition to outstanding trial experience, GPW is backed by a large arsenal of corporate documents, depositions, and medical articles with which to vigorously prosecute your asbestos case.

Nutritional Support

Haelan Products offers Haelan 951, an international award-winning, super nutritious, fermented soybean protein beverage. Clinical research and numerous reports from doctors and cancer patients have demonstrated that Haelan 951 helps protect cancer patients from the toxic side-effects of chemotherapy and radiation treatments. In addition, one study found that the soy isoflavone genistein (which is found in Haelan 951) produced greater apoptosis with both chemotherapy and radiation treatments. Apoptosis means “programmed cell death” and it is a goal of most orthodox cancer therapies. Because Haelan 951 is a nutritional supplement, not a cancer treatment, it was used in this study to offset the toxicity of the treatments, not as a cancer therapy.

Questions? Sponsorship Inquiries? Interview Inquiries? Contact:

Copyright 2006 Cancer Monthly